A1chieve Program in Russian Federation: a multicenter prospective observational study of insulin analogue treatment efficiency and safety in daily management of patients with type 2 diabetes mellitus, who startand intensify insulin treatment having never received it before

Prevalence rate of diabetes mellitus worldwide and in Russian Federation is epidemic in its nature. Prospective studies have shown thatmaintenance of glycemic target reduces risk of late vascular complications. In turn, strict glycemic control requires modern approach tointensification of glucose lo...

Full description

Bibliographic Details
Main Author: Marina Vladimirovna Shestakova
Format: Article
Language:English
Published: Endocrinology Research Centre 2012-03-01
Series:Сахарный диабет
Subjects:
Online Access:https://dia-endojournals.ru/dia/article/viewFile/5981/3740
id doaj-35253e7c4a53459592ef9b11416ba12a
record_format Article
spelling doaj-35253e7c4a53459592ef9b11416ba12a2021-06-02T21:12:30ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782012-03-01151637010.14341/2072-0351-59815939A1chieve Program in Russian Federation: a multicenter prospective observational study of insulin analogue treatment efficiency and safety in daily management of patients with type 2 diabetes mellitus, who startand intensify insulin treatment having never received it beforeMarina Vladimirovna Shestakova0Endocrinology Research Centre, MoscowPrevalence rate of diabetes mellitus worldwide and in Russian Federation is epidemic in its nature. Prospective studies have shown thatmaintenance of glycemic target reduces risk of late vascular complications. In turn, strict glycemic control requires modern approach tointensification of glucose lowering therapy. Randomized clinical trials prove capacity of modern insulin analogues to improve glycemiccontrol while decreasing risk of hypoglycemic events and weight gain. Current paper presents initial data on 9342 patients, participatedin multicenter prospective 52-week observational study A1chieve, conducted in order to assess efficiency and safety of treatment withinsulin analogues Levemir?, NovoMix? and NovoRapid? (Novo Nordisk) in daily management of patients with type 2 diabetes mellitus,who never received that treatment before.https://dia-endojournals.ru/dia/article/viewFile/5981/3740diabetes mellitus type 2observational study a1chieveinsulin analogues
collection DOAJ
language English
format Article
sources DOAJ
author Marina Vladimirovna Shestakova
spellingShingle Marina Vladimirovna Shestakova
A1chieve Program in Russian Federation: a multicenter prospective observational study of insulin analogue treatment efficiency and safety in daily management of patients with type 2 diabetes mellitus, who startand intensify insulin treatment having never received it before
Сахарный диабет
diabetes mellitus type 2
observational study a1chieve
insulin analogues
author_facet Marina Vladimirovna Shestakova
author_sort Marina Vladimirovna Shestakova
title A1chieve Program in Russian Federation: a multicenter prospective observational study of insulin analogue treatment efficiency and safety in daily management of patients with type 2 diabetes mellitus, who startand intensify insulin treatment having never received it before
title_short A1chieve Program in Russian Federation: a multicenter prospective observational study of insulin analogue treatment efficiency and safety in daily management of patients with type 2 diabetes mellitus, who startand intensify insulin treatment having never received it before
title_full A1chieve Program in Russian Federation: a multicenter prospective observational study of insulin analogue treatment efficiency and safety in daily management of patients with type 2 diabetes mellitus, who startand intensify insulin treatment having never received it before
title_fullStr A1chieve Program in Russian Federation: a multicenter prospective observational study of insulin analogue treatment efficiency and safety in daily management of patients with type 2 diabetes mellitus, who startand intensify insulin treatment having never received it before
title_full_unstemmed A1chieve Program in Russian Federation: a multicenter prospective observational study of insulin analogue treatment efficiency and safety in daily management of patients with type 2 diabetes mellitus, who startand intensify insulin treatment having never received it before
title_sort a1chieve program in russian federation: a multicenter prospective observational study of insulin analogue treatment efficiency and safety in daily management of patients with type 2 diabetes mellitus, who startand intensify insulin treatment having never received it before
publisher Endocrinology Research Centre
series Сахарный диабет
issn 2072-0351
2072-0378
publishDate 2012-03-01
description Prevalence rate of diabetes mellitus worldwide and in Russian Federation is epidemic in its nature. Prospective studies have shown thatmaintenance of glycemic target reduces risk of late vascular complications. In turn, strict glycemic control requires modern approach tointensification of glucose lowering therapy. Randomized clinical trials prove capacity of modern insulin analogues to improve glycemiccontrol while decreasing risk of hypoglycemic events and weight gain. Current paper presents initial data on 9342 patients, participatedin multicenter prospective 52-week observational study A1chieve, conducted in order to assess efficiency and safety of treatment withinsulin analogues Levemir?, NovoMix? and NovoRapid? (Novo Nordisk) in daily management of patients with type 2 diabetes mellitus,who never received that treatment before.
topic diabetes mellitus type 2
observational study a1chieve
insulin analogues
url https://dia-endojournals.ru/dia/article/viewFile/5981/3740
work_keys_str_mv AT marinavladimirovnashestakova a1chieveprograminrussianfederationamulticenterprospectiveobservationalstudyofinsulinanaloguetreatmentefficiencyandsafetyindailymanagementofpatientswithtype2diabetesmellituswhostartandintensifyinsulintreatmenthavingneverreceiveditbefore
_version_ 1721400671150800896